Please assess the completion status of the following clinical trial:

Trial Title: The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1) age 18-80 years~* 2) American Society of Anesthesiologist (ASA) classification score I\~III~Exclusion Criteria:~* 1) allergic to tranexamic acid~* 2) preoperative seizures~* 3) history of thrombotic disease~* 4) chronic kidney disease~* 5) breastfeeding or pregnancy~* 6) refuse to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TXA group (Type: ACTIVE_COMPARATOR): The TXA group will receives Tranexamic acid intraoperative.
- Placebo group (Type: PLACEBO_COMPARATOR): The TXA group will receives 0.9% saline intraoperative.

Based on this trial design, predict the completion outcome and termination type (if applicable).